Vaccination of Vaccinia-Naive Adults with Human Immunodeficiency Virus Type 1 gpl60 Recombinant Vaccinia Virus in a Blinded, Controlled, Randomized Clinical Trial

Journal of Infectious Diseases

Volumn 166, Issue 2, 1992, Pages 244-252

  Graham, Barney S ^a,b,c,d,e,f   Belshe, Robert B ^a,b,c,d,e,f   Clements, Mary Lou ^a,b,c,d,e,f   Dolin, Raphael ^a,b,c,d,e,f   Corey, Lawrence ^a,b,c,d,e,f   Wright, Peter F ^a,b,c,d,e,f   Gorse, Geoffrey J ^a,b,c,d,e,f   Midthun, Karen ^a,b,c,d,e,f   Keefer, Michael C ^a,b,c,d,e,f   Roberts, Norbert J ^a,b,c,d,e,f   Schwartz, David H ^a,b,c,d,e,f   Agosti, Jan M ^a,b,c,d,e,f   Fernie, Bruce F ^a,b,c,d,e,f   Stablein, Donald M ^a,b,c,d,e,f   Montefiori, David C ^a,b,c,d,e,f   Lambert, John S ^a,b,c,d,e,f   Hu, Shiu Lok ^a,b,c,d,e,f   Esterlitz, Joy R ^a,b,c,d,e,f   Lawrence, Dale N ^a,b,c,d,e,f   Koff, Wayne C ^a,b,c,d,e,f  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG STABILITY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INTRADERMAL DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VACCINIA VIRUS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS VACCINES; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; DOUBLE-BLIND METHOD; FEMALE; GENE PRODUCTS, ENV; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP160; HIV-1; HUMAN; IMMUNIZATION, SECONDARY; LEUKOCYTE COUNT; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGE; PROTEIN PRECURSORS; SUPPORT, U.S. GOV'T, P.H.S.; VACCINATION; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRUS REPLICATION;

EID: 0026734288     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/166.2.244     Document Type: Article

References (36)

1. Mackett M, Smith GL, Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA 1982; 79:7415-9.
2. Panicali D. Paoletti E. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci USA 1982;79:4927-31.
3. Smith G, Murphy BR, Moss B. Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci USA 1983;80:7155-9.
4. Wiltor TJ. Mucfarlan RI, Reagan K. J. et al. Protection from rabies by vaccinia virus recombinant containing the rabies glycoprotein gene. Proc Natl Acad Sci USA 1984;81:7194-8.
5. Paoletti E. Lipinskas BR, Samsonoff C, MercerS, Panicali D. Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci USA 1984:81:193-7.
6. Mackett M, Yilma IRose JK, Moss B. Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle. Science 1985;227:433-5.
7. Yilma T. Hsu D, Jones L, et al. Protection of cattle against rinderpest with vaccinia virus recombinants expressing the HA or F gene. Science 1988;242:1058-61.
8. Moss B, Smith GL, Gerin JL. Purcell RH. Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature 1984;311:67-9.
9. Hu SL, Zarling JM, Chin J, et al. Protection of macaques against simian AIDS by immunization with a recombinant vaccinia virus expressing the envelope glycoprotein of simian type D retrovirus. Proc Natl Acad Sci USA 1989;86:7213-7.
10. Bcnnick JR, Yewdell J W, Smith GL. Moller C, Moss B. Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-speci-fic cytotoxic T cells. Nature 1984;311:578-9.
11. Shen L. Chen ZW, Miller MD. et al. Recombinant virus vaccine-induced SIV-specific CD84-cytotoxic T lymphocytes. Science 1991;252:440-3.
12. Gotch FM, Hovell R, Delchambre M. Silvera P, McMichael AJ. Cytotoxic T-cell response to simian immunodeficiency virus by cynomol-gus macaque monkeys immunized with recombinant vaccinia virus. AIDS 1991;5:317-20.
13. Chakrabarti S. Robert-Guroff M, Wong-Staal F, Gallo RC, Moss B. Expression of the HTLV-II1 envelope gene by a recombinant vaccinia virus. Nature 1986;320:535-7.
14. Hu SL, Kosowski SG, Dalrymple JM. Expression of AIDS virus envelope gene in recombinant vaccinia viruses. Nature 1986;320:537-9.
15. Zarling JM, Fichberg JW, Moran PA, McClure J, Sridhar P, Hu SL. Proliferative and cytotoxic T ceils to AIDS virus glycoproteins in chimpanzees immunized with a recombinant vaccinia virus expressing AIDS virus envelope glycoproteins. J Immunol 1987; 139:988-90.
16. Jones L, Ristow S, Yilma T, Moss B. Accidental human vaccination with vaccinia virus expressing nucleoprotein gene. Nature 1986:319:543.
17. Openshaw PJM, Alwan WH, Cherrie AH. Record FM. Accidental infection of laboratory worker with recombinant vaccinia virus. Lancet 1991;338:459.
18. Zagury D, Léonard R. Fouchard M. et al. Immunization against AIDS in humans. Nature 1987;326:249-50.
19. Zagury D, Bernard J. Cheynier R, et al. A group specific anamnesticimmune reaction against HIV-1 induced by a candidate vaccine against AIDS. Nature 1988;332:728-31.
20. Cooney EL, Collier AC, Greenberg PD, et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991:337:567-72.
21. Kniker WT, Anderson CT. Roumeanlxeff M. The MULTITEST system: a standardized approach to evaluation of delayed hypersensitivity and cell mediated immunity. Ann Allergy 1979;43:73-9.
22. Fenner F, Henderson DA, Arita I. Jezek Z, Ladnyi ID. Smallpox and its eradication. Geneva: World Health Organization. 1988.
23. Montefiori DC, Robinson WH. Schuffman SS, Mitchell WM. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J Clin Microbiol 1988;26:231-5.
24. Graham BS. Bunton LA, Wright PF, Karzon DT. Reinfection of mice with respiratory syncytial virus. J Med Virol 1991;34:7-13.
25. Breman JG, Arita I. The confirmation and maintenance of smallpox eradication. N Engl J Med 1980;303:1263-73.
26. Baumgaertner JC, Hogan R, Borm C. Berg J, Davis JP. Contact spread of vaccinia from a National Guard vaccinee. MMWR 1985;34:182-3.
27. Goldstein JA, Neff JM, Lane JM, Koplan JP. Smallpox vaccination reactions, prophylaxis, and therapy of complications. Pediatrics 1975;55:342-7.
28. Redfield RR, Wright DC, James WD. Jones TS, Brown C, Burke DS. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N F. ngl J Med 1987;316:673-6.
29. Picard O, Giral P, Defer MC, et al. AIDS vaccine therapy: phase I trial. Lancet 1990;336:179.
30. Guillaume JC, Saiag P, Wechsler J, Lescs MC, Roujeau JC. Vaccinia from recombinant virus expressing HIV genes. Lancet 1991:337: 1034-5.
31. Buller RML, Smith GL, Cremer K., Notkins AL, Moss B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 1985;317:813-5.
32. Taylor G, Stott EJ, Wertz G. Ball A. Comparison of the virulence of wild-type thymidine kinase (tk)-deficient and tk+ phenotypes of vaccinia virus recombinants after intranasal inoculation of mice. J Gen Virol 1991;72:125-30.
33. Dolin R, Graham B. Greenberg SB, et al. Safety and immunogenicity of an HIV-1 recombinant gp 160 candidate vaccine in humans. Ann Intern Med 1991; 114:1 19-27.
34. Hu SL, Klaniecki J, Dykers T, Sridhar P, Travis BM. Neutralizing antibodies against HIV-1 BRU and SF-2 isolates generated in mice expressing HIV-1 envelope glycoproteins and boosted with gp 160. AIDS Res Hum Retroviruses 1991;7:615-20.
35. Hu SL, Abrams K, Barber GN, et al. Protection of macaques against SIV infection by subunil vaccines of SIV envelope glycoprotein gp 160. Science 1992;255:456-9.
36. Graham BS, Belshe R. Clements ML. et al. HIV-gpl60 recombinant vaccinia vaccination of vaccinia-naive adults followed by rgp 160 booster immunization [abstract F. A. l. J In: Program and abstracts of the VII International Conference on AIDS (Florence. Italy). Rome: Instituto Superiore di Sanità, 1991.